Results 201 to 210 of about 38,997 (290)

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 5, Page 766-780, May 2026.
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu   +4 more
wiley   +1 more source

Engineering Marker‐Free Lettuce Chloroplast Genome to Express Functional Glucagon‐Like Peptide‐1 Receptor Agonists Exenatide and Lixisenatide

open access: yesPlant Biotechnology Journal, Volume 24, Issue 5, Page 3158-3171, May 2026.
Engineering of marker‐free lettuce chloroplast genome to express CTB‐Exenatide and CTB‐Lixisenatide for oral delivery. Upper panel: Chemically synthesised exenatide or lixisenatide require expensive production, purification, refrigeration and invasive delivery methods.
Rahul Singh, Henry Daniell
wiley   +1 more source

Case Report: When genetic diagnosis comes late: lessons from a DEND syndrome patient successfully transitioned to sulfonylurea. [PDF]

open access: yesFront Clin Diabetes Healthc
Abreu GM   +15 more
europepmc   +1 more source

Stacked mutations in multi-copy AHAS genes enhance sulfonylurea herbicide resistance in soybean. [PDF]

open access: yesPlant J
Park K   +11 more
europepmc   +1 more source

Sex Differences in [ 68Ga]Ga‐NODAGA‐Exendin‐4 Uptake in the Pituitary of Individuals With Type 2 Diabetes

open access: yes
Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4387-4390, May 2026.
Sevilay Tokgöz   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy